This study focuses on individuals who have a type of breast cancer called triple-negative breast cancer (and who are not surgical candidates) or whose cancer is metastatic (spread to other parts of the body) and have not received prior therapy for metastatic disease. The study will evaluate an experimental drug called RO7247669 used in combination with nab-paclitaxel (a common type of chemotherapy used to treat breast cancer). Researchers will compare the effects of RO7247669 versus another drug, pembrolizumab (in combination with nab-paclitaxel). Participants will receive either RO7247669 in combination with nab paclitaxel or pembrolizumab in combination with nab-paclitaxel. By blocking specific proteins in cells, RO7247669 may help the immune system stop or reverse the growth of tumors. Pembrolizumab is approved by the U.S. Food and Drug Administration (FDA) for various types of cancer, but its use in this study is considered investigational.
What is the full name of this clinical trial?
CO44194: A Phase II, Multicenter, Randomized, Double-Blind Study of RO7247669 Combined With Nab-Paclitaxel Compared With Pembrolizumab Combined With Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer